British and Finnish drug developers plan London IPOs
11 September 2015
The moves come despite recent market volatility, triggered by fears about Chinese growth prospects, which have led to a sharp correction in U.S. biotechnology stocks after a 2-1/2-year boom. Although the London stock market was slower to catch the biotech bug initially, it has seen a steady build up in initial public offerings (IPOs) and venture funding, with public and private fundraisings hitting a 10-year high in 2014, according to the British Bioindustry Association.
New Market Research Report: Russia Pharmaceuticals & Healthcare Report Q3 2015
11 September 2015
Multinational pharmaceutical companies will experience greater challenges over the coming year as Russia's grim economic outlook will have a significant impact on consumer demand for pharmaceuticals . Furthermore, government measures, such as the introduction of further price controls, will hurt revenues of innovative and generic drugmakers.
Another Indian firm draws WHO notice on testing, manufacturing concerns
11 September 2015
Indian company Svizera Labs has drawn a rebuke from the World Health Organization (WHO) for flawed manufacturing standards and testing procedures of tuberculosis drugs made for export to developing countries, the latest in a string of regulatory rebukes facing drugmakers in the country.
The new pace of venture capital fundraising? Why early stage VCs are fundraising faster than ever
10 September 2015
Many would agree that company financing dynamics in venture capital have changed in recent years, especially with respect to valuations rising, round sizes increasing and companies staying private for longer. From my vantage point, these dynamics are contributing to an accelerating pace of VC fundraising. The story told below using PitchBook data explains partly why early stage VCs have been coming back to fundraise faster and why this trend may persist if financing dynamics continue at their current pace.
NIH backs research to put genomic data into electronic medical records
10 September 2015
As researchers home in on the genetic underpinnings of disease, the National Institutes of Health (NIH) is awarding a dozen grants to scientists who are exploring ways to combine genomic test information with electronic health records to improve care for patients.
Volatile valuations make biotech a haven for short sellers
10 September 2015
The years-long glut of biotech IPOs has flooded the public markets with high-risk life sciences companies, and shorts have taken a particular interest in those newly public drug developers, according to a report, betting the industry's recent boom will see its shadow.
09 September 2015
Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA). The objective of the meeting was to obtain FDA feedback on the nonclinical and clinical programs to support registration of ganaxolone for the adjunctive treatment of focal onset seizures in adults.
Pharma's new patent worry by the numbers: No 'IP death squad' here, analyst says
09 September 2015
According to an analysis of past IPR challenges, not a lot, Bernstein analyst Ronny Gal wrote in a Thursday note to clients. In 165 pharma cases so far, only 88 have gone through a decision on whether to institute review proceedings. Of those 88, the U.S. Patent and Trademark Office (PTO) has only chosen to fully institute proceedings 41 times, or in 47% of cases. That rate is "remarkably lower" than the 75%-plus rate across all sectors, which includes tech, he pointed out.
Pharma market bets on ASEAN in focus ahead of economic pact
09 September 2015
At the end of 2015, the Association of Southeast Asian Nations (ASEAN) will launch an economic union in a region that has already seen a slew of device and drug companies contemplate, start or expand hubs in Singapore to sell into nearby markets.
Pharma Faces More Comparisons of Drug Costs and Effectiveness
09 September 2015
Will emerging drug cost assessment initiatives provide useful, valid information on total drug value? Or will new “scores” on drug cost-effectiveness merely justify more no-coverage decisions by insurers and health plans? These are troubling prospects for biopharma companies, as well as for patients and prescribers, as medical authorities and health care analysts look to more broadly incorporate drug costs into treatment evaluations and recommendations.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024